RESEARCH TRIANGLE PARK, N.C. – September 2, 2008 – NovaQuest, the managed partnership group of Quintiles Transnational Corp., has received Eli Lilly and Company’s highest award for its “flawless execution” over four years in helping Lilly achieve strategic and operational objectives vital to its business success.

In honoring NovaQuest with its “2008 Lilly Global Sustained Supplier Award,” Lilly cited NovaQuest’s ability to create, manage and execute strategic partnerships that have helped Lilly meet critical corporate priorities. Lilly CEO John Lechleiter presented the award to NovaQuest President Ron Wooten.

“We are proud to have received this award, which recognizes the ongoing success Lilly and NovaQuest have achieved since our initial partnership in 2004 to co-promote Cymbalta®, Lilly’s blockbuster treatment for depression, in the United States,” said Wooten, who also is Executive Vice President of Quintiles Transnational.

“Success breeds trust, and we are proud of our role in helping Lilly transform its business model to deliver better patient outcomes. We look forward to continued mutually beneficial successes in both commercialization and development.”

NovaQuest is the partner of choice for pharmaceutical and biotechnology companies seeking to overcome challenges stifling their product development, commercialization and financial goals. The managed partnership group of Quintiles Transnational, NovaQuest uniquely offers accelerated pipeline development, flexible resourcing, new capital streams and access to senior-level expertise. Since 2000, NovaQuest has created more than 80 managed partnerships with $2.7 billion committed to helping its partners accelerate their strategy and transform their businesses to reach new heights of success.